Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data

This is a summary. Read the complete story at Investing.com below.

Related Stories

stocksabout 2 hours ago

GS flags interest rates and AI disruption as risks to long-term equity demand

Investing.com

stocksabout 3 hours ago

Tech risk-reward turns favorable after rout, Deutsche Bank says

Investing.com

stocksabout 3 hours ago

Power bills and data centers cast rare spotlight on utilities in US midterms

Investing.com